Roivant Sciences Ltd. (ROIV)

11.03 +0.15 (+1.38%) At close: 04:00PM EDT

Roivant Sciences Ltd.

50 Broadway
7th Floor
London SW1H 0DB
United Kingdom
44 20 7400 3347
https://roivant.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 904

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Matthew Gline	CEO & Director	1.77M	N/A	1984
Dr. Eric Venker M.D., Pharm.D.	President & COO	1.28M	N/A	1987
Dr. Mayukh Sukhatme M.D.	President, Chief Investment Officer & Director	1.72M	N/A	1976
Mr. Richard Pulik	Chief Financial Officer	N/A	N/A	1979
Ms. Rakhi Kumar	Chief Accounting Officer	N/A	N/A	1980
Dr. Huafeng Xu Ph.D.	Chief Technology Officer	N/A	N/A	N/A
Mr. Jo Chen	General Counsel	N/A	N/A	N/A
Ms. Kelly Graff	Head of People	N/A	N/A	N/A
Ms. Marianne L. Romeo	Head of Global Transactions & Risk Management	N/A	N/A	1968
Mr. Alex Gasner	Executive Vice President of Roivant Health	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Corporate governance

Roivant Sciences Ltd.’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 8; Board: 6; Shareholder rights: 4; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.